[Table/Fig-2]:
Different type of vaccines in clinical trial or effective in Non Human Primates (NHPs).
| S. No. | Type of Vaccines |
Key component | Efficacy | Adverse effect |
|---|---|---|---|---|
| 1 | Conventional Vaccines | Inactivation of EBOV by heat, formalin, or γ-irradiation | not effective | significant risk of reversion |
| 2 | Sub-Unit Vaccines (Non- Viral) | Ebola virus genes inserted into a DNA plasmid | Full protection was reported in mice and later in guinea pigs with optimized strategies | - |
| 3 | Virus-like Particles (VLPs) as a Candidate Vaccine | EBOV-like particles generated by the expression of VP40 alone or along with GP. | Full Protection | - |
| 4 | Vector-Based Vaccines | 1. not be recommended for use in immuno- compromised individuals 2. Pre existing immunity against viral vector decreases immune response 3. Multiple doses required |
||
| a. Vaccinia virus-based vaccines. | recombinant vaccinia virus | incomplete protection in guinea pigs, no protection in NHPs | ||
| b. VEE virus-like replicon particles | recombinant Venezuelan equine encephalitis (VEE) virus | Fully protective in mice, no protection in NHPs | ||
| c. Adenovirus- Based Vaccines. | recombinant human adenovirus serotype-5 (AdHu5) virus | complete protection in NHPs | ||
| d. Vesiculovirus (VSV)-based candidate vaccines. | recombinant VSV | 100% protection in mice, 50% protection in guinea pigs and NHPs | ||